TARSUS PHARMACEUTICALS INC
TARSNASDAQTrading Snapshot
- Day Range
- $76.30 – $77.40
- 52-Week Range
- $53.89 – $91.53
- Volume
- $2.86B
- Avg Volume
- $3.77B
- Shares Outstanding
- 43.0M
- Next Earnings
- Dec 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $451M
- Last Q Revenue
- $174M
- P/E Ratio
- —
- P/S Ratio
- 5.9x
- EPS (TTM)
- $-1.08
- Dividend Yield
- —
- Dilution (1yr)
- +11.0%
Why Investors Own TARS
- ✓High-growth profile — revenue up +45.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 39% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TARSUS PHARMACEUTICALS INC
TARS
StockOtter · stockotter.spaceAbout TARSUS PHARMACEUTICALS INC
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (AAOpt) 2026 Annual M
Citius Pharmaceuticals (NASDAQ:CTXR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Financial Analysis
Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) and Tarsus Pharmaceuticals (NASDAQ: TARS - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved therapy Strengthe
114,458 Shares in Tarsus Pharmaceuticals, Inc. $TARS Bought by Bank of New York Mellon Corp
Bank of New York Mellon Corp bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission
Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease
Daily treatment with oral gildeuretinol met the primary endpoint and resulted in a statistically significant reduction in the growth rate of retinal atrophic lesions compared to untreated group. Gildeuretinol was well to
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Wells Fargo 21st Annual Healthc